文献速递产科母胎医学

孕激素预防早产与妊娠期糖尿病发病风险:一项Meta分析

Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2019-05-24

该Meta分析纳入11项随机试验和观察性研究、共8085名孕妇,评估孕期补充孕激素预防早产与妊娠期糖尿病风险的关联。结果显示,接受17α-羟孕酮己酸酯者妊娠期糖尿病风险升高(风险比1.73,95%CI 1.32-2.28),阴道用孕酮者风险比为0.82(95%CI 0.50-1.12),未达统计学显著。

要点

  • 接受17α-羟孕酮己酸酯者妊娠期糖尿病风险升高(RR 1.73,95%CI 1.32-2.28)。
  • 阴道用孕酮者RR 0.82(95%CI 0.50-1.12),未达统计学显著。
  • 作者结论认为,阴道用孕酮相关证据仍不确定。

核心结论

  • 作者结论认为,补充17α-羟孕酮己酸酯用于预防早产的女性妊娠期糖尿病风险升高。

研究设计与样本

  • Meta分析,检索Medline(1966-2019)、Scopus(2004-2019)、Clinicaltrials.gov(2008-2019)、EMBASE(1980-2019)、Cochrane CENTRAL(1999-2019)和Google Scholar(2004-2019)。
  • 纳入随机试验和观察性研究,不设语言、国家和日期限制,共纳入11项研究、8085名女性。
  • 采用Cochrane偏倚风险工具和ROBINS-I工具评价方法学质量,用RevMan 5.3进行Meta分析,并用Open Meta-Analyst做二次分析,另进行试验序贯分析。

主要发现

  • 接受17α-羟孕酮己酸酯者妊娠期糖尿病风险升高(风险比1.73,95%CI 1.32-2.28)。
  • 接受阴道用孕酮者风险比为0.82(95%CI 0.50-1.12),因置信区间估计不稳定,未达统计学显著。
  • Meta回归显示,妊娠期糖尿病作为主要或次要结局(协方差系数-0.36,95%CI -0.85至0.13,P=.154)及研究类型(随机对照试验/观察性研究)(协方差系数-0.361,95%CI -1.049至0.327,P=.304)均未显著改变主要分析结果。
  • 试验序贯分析提示,关于17α-羟孕酮己酸酯相关性的Meta分析把握度充分,可得出确定结论,而阴道用孕酮未获此确认。

局限性

  • 作者结论指出,阴道用孕酮相关证据仍不确定(remains inconclusive)。
  • Meta回归中妊娠期糖尿病作为主要或次要结局的协方差系数95%CI为-0.85至0.13(P=.154),研究类型的协方差系数95%CI为-1.049至0.327(P=.304),均未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several articles have implied that progestogen supplementation during pregnancy to reduce the risk of preterm birth may increase the risk for developing gestational diabetes mellitus. OBJECTIVE: The purpose of the present meta-analysis was to accumulate existing evidence concerning this correlation. DATA SOURCES: We searched Medline (1966-2019), Scopus (2004-2019), Clinicaltrials.gov (2008-2019), EMBASE (1980-2019), Cochrane Central Register of Controlled Trials CENTRAL (1999-2019), and Google Scholar (2004-2019) databases. STUDY ELIGIBILITY CRITERIA: Randomized trials and observational studies were considered eligible for inclusion in the present meta-analysis. To minimize the possibility of article losses, we avoided language, country, and date restrictions. STUDY APPRAISAL AND SYNTHESIS METHODS: The methodological quality of included studies was evaluated with the Cochrane risk of bias and the Risk Of Bias In Non-Randomized Studies of Interventions (ROBINS-I) tool. Meta-analysis was performed with the RevMan 5.3 and secondary analysis with the Open Meta-Analyst software. Trial sequential analysis was conducted with the trial sequential analysis program. RESULTS: Overall, 11 studies were included in the present meta-analysis that recruited 8085 women. The meta-analysis revealed that women who received 17-alpha hydroxyprogesterone caproate had increased the risk of developing gestational diabetes mellitus (risk ratio, 1.73, 95% confidence interval, 1.32-2.28), whereas women who received vaginal progesterone had a decreased risk, although the effect did not reach statistical significance because of the unstable estimate of confidence intervals (risk ratio, 0.82, 95% confidence interval, 0.50-1.12). Meta-regression analysis indicated that neither the methodological rationale for investigating the prevalence of gestational diabetes mellitus (incidence investigated as primary or secondary outcome) (coefficient of covariance, -0.36, 95% confidence interval, -0.85 to 0.13, P = .154) nor the type of investigated study (randomized controlled trial/observational) (coefficient of covariance -0.361, 95% confidence interval, -1.049 to 0.327, P = .304) significantly altered the results of the primary analysis. Trial sequential analysis suggested that the meta-analysis concerning the correlation of 17-alpha hydroxyprogesterone caproate was of adequate power to reach firm conclusions, whereas this was not confirmed in the case of vaginal progesterone. CONCLUSION: The results of the present meta-analysis clearly indicate that women who receive supplemental 17-alpha hydroxyprogesterone caproate for the prevention of preterm birth have an increased risk of developing gestational diabetes mellitus. On the other hand, evidence concerning women treated with vaginal progesterone remains inconclusive.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pergialiotis V, Bellos I, Hatziagelaki E, et al. Progestogens for the prevention of preterm birth and risk of developing gestational diabetes mellitus: a meta-analysis. Am J Obstet Gynecol. 2019. PMID: 31132340. doi:10.1016/j.ajog.2019.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。